公开(公告)号：US09081016B2

公开(公告)日：2015-07-14

申请号：US13766130

申请日：2013-02-13

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Veit Peter Grunert ,  Ursula Klause ,  Pavel Kubalec ,  Matthias Rothfuss ,  Barbara Upmeier

IPC: C40B30/04 ,  G01N33/68

CPC classification number: G01N33/6854 ,  C40B30/04 ,  G01N2800/52

Abstract: Methods and system for determination of an anti- antibody (anti- AB) in vitro in a sample from a patient treated with a therapeutic monoclonal antibody (TmAB). Also, methods and systems for the determination of antigen specific antibodies of a particular immunoglobulin class and for the identification of a patient who is at risk of developing an adverse drug reaction (ADR) during treatment with a TmAB.

Abstract translation: 在用治疗性单克隆抗体（TmAB）治疗的患者的样品中体外测定抗<治疗性单克隆抗体>抗体（抗-TABAB> AB）的方法和系统。 而且，用于确定特定免疫球蛋白类别的抗原特异性抗体的方法和系统以及用于在用TmAB治疗期间鉴定患有不良药物反应（ADR）的风险的患者的方法和系统。

公开(公告)号：US20150192583A1

公开(公告)日：2015-07-09

申请号：US14462802

申请日：2014-08-19

Applicant: Roche Diagnostics Operations, Inc. ,  Academic Medical Center at the University of Amsterdam

Inventor： Ursula Klause ,  Berthold Hipp ,  Veit Peter Grunert ,  Barbara Upmeier ,  Uri Lopatin ,  Annikki de Niet ,  Henk Reesink ,  Hans Zaaijer

IPC: G01N33/569

CPC classification number: G01N33/56983 ,  G01N33/564 ,  G01N33/5761 ,  G01N2333/02 ,  G01N2800/52

Abstract: The present invention relates to a method for identifying a subject suffering from hepatitis B virus (HBV) infection as being susceptible to interferon treatment, said method comprising the steps of a) determining, in a sample of said subject, the amount of HBV immune complexes, b) comparing the amount of HBV immune complexes obtained in step a) to a reference value, and c) identifying a subject suffering from HBV infection as being susceptible to interferon treatment based on the result of the comparison made in step b). The present invention further relates to the use of the determination of the amount of HBV immune complexes in a sample from a subject suffering from HBV infection and of a detection agent for HBV immune complexes for identifying a subject suffering from HBV infection as being susceptible to interferon treatment. Furthermore, the present invention relates to a device and a kit allowing identifying a subject suffering from HBV infection as being susceptible to interferon treatment.

Abstract translation: 本发明涉及用于鉴定患有乙型肝炎病毒（HBV）感染的受试者易于进行干扰素治疗的方法，所述方法包括以下步骤：a）在所述受试者的样品中测定HBV免疫复合物的量 b）将步骤a）中获得的HBV免疫复合物的量与参考值进行比较，以及c）根据步骤b）中进行的比较结果，鉴定患有HBV感染的受试者易于进行干扰素治疗。 本发明还涉及确定来自患有HBV感染的受试者的样品中的HBV免疫复合物的量和HBV免疫复合物的检测剂用于鉴定患有HBV感染的受试者对于干扰素敏感的用途的用途 治疗。 此外，本发明涉及允许将患有HBV感染的受试者识别为易于进行干扰素治疗的装置和试剂盒。

公开(公告)号：US20130157892A1

公开(公告)日：2013-06-20

申请号：US13766130

申请日：2013-02-13

Applicant: ROCHE DIAGNOSTICS OPERATIONS, INC.

Inventor： Veit Peter Grunert ,  Ursula Klause ,  Pavel Kubalec ,  Matthias Rothfuss ,  Barbara Upmeier

IPC: G01N33/68

CPC classification number: G01N33/6854 ,  C40B30/04 ,  G01N2800/52

Abstract: Methods and system for determination of an anti- antibody (anti- AB) in vitro in a sample from a patient treated with a therapeutic monoclonal antibody (TmAB). Also, methods and systems for the determination of antigen specific antibodies of a particular immunoglobulin class and for the identification of a patient who is at risk of developing an adverse drug reaction (ADR) during treatment with a TmAB.

Abstract translation: 在用治疗性单克隆抗体（TmAB）治疗的患者的样品中体外测定抗<治疗性单克隆抗体>抗体（抗-TABAB> AB）的方法和系统。 而且，用于确定特定免疫球蛋白类别的抗原特异性抗体的方法和系统以及用于在用TmAB治疗期间鉴定患有不良药物反应（ADR）的风险的患者的方法和系统。